Vanderbilt Phase I Translational Research Program

Rothenberg, Mace L.

Abstract

Funding Agency

• Agency: National Institute of Health (NIH)
• Institute: National Cancer Institute (NCI)
• Type: Research Project--Cooperative Agreements (U01)
• Project #: 5U01CA099177-02
• Application #: 6721315
• Study Section: Special Emphasis Panel (ZCA1-SRRB-E (O1))
• Program Officer: Jensen, Leeann T
• Project Start: 2003-03-14
• Project End: 2008-02-28
• Budget Start: 2004-04-15
• Budget End: 2005-02-28
• Support Year: 2
• Fiscal Year: 2004
• Total Cost: $117,499

Institution

• Name: Vanderbilt University Medical Center
• Department: Internal Medicine/Medicine
• Type: Schools of Medicine
• DUNS #: 004413456
• City: Nashville
• State: TN
• Country: United States
• Zip Code: 37212

Publications

Puzanov, Igor; Lee, Wooin; Chen, Alice P et al. (2011) Phase I pharmacokinetic and pharmacodynamic study of SJG-136, a novel DNA sequence selective minor groove cross-linking agent, in advanced solid tumors. Clin Cancer Res 17:3794-802

Wade Calcutt, M; Lee, Wooin; Puzanov, Igor et al. (2008) Determination of chemically reduced pyrrolobenzodiazepine SJG-136 in human plasma by HPLC-MS/MS: application to an anticancer phase I dose escalation study. J Mass Spectrom 43:42-52

Albert, Jeffrey M; Cao, Carolyn; Kim, Kwang Woon et al. (2007) Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clin Cancer Res 13:3033-42